News – Page 989 – Endpoints News

Carving a pipeline out of troubled Teva, OrbiMed leads $60M launch of new NASH player

7 years ago

Novo-backed Galecto Biotech scores €79 million in Series C funding

7 years ago

Constipation drug maker Synergy looks to renegotiate bloated loan agreement — shares tumble

7 years ago

Fight! Trump kicks off a war of words with the drug lobby, proposing to peg Medicare prices to overseas rates

7 years ago

Deborah Dunsire kicks off her new gig as Lundbeck CEO with a key PhIII trial failure

7 years ago

Vertex cleans up its pipeline; FDA grants priority review to Jakafi for GVHD

7 years ago

Biogen, Eisai fight back against accusations their big BAN2401 study was skewed -- but this fight isn't over yet

7 years ago

Milestone Pharma grabs an $80M round as it steams into pivotal trial work, starts outlining commercial structure

7 years ago

FDA kicks Regeneron’s latest Eylea application to the curb, but they’re not sweating it

7 years ago

Mixed data doesn't stop this biotech unicorn from plotting a looming PhIII showdown

7 years ago

As talk of drug pricing takes center stage, Amgen slashes Repatha price by nearly 60%

7 years ago

Trump to unveil proposal to reduce prices on doctor-administered drugs as midterms loom

7 years ago

Roche's new, single-dose flu drug gets the green light at a hard charging FDA, breaking into record-setting territory

7 years ago

AbbVie is going for it in cystic fibrosis. But why are they buying the weak Galapagos portfolio in a $245M deal?

7 years ago

Bayer, Orion prostate cancer drug delays spread of disease in PhIII, but can it make a mark in a crowded market?

7 years ago

Our Alzheimer's drug was not a complete bust, says vTv; Xtalpi raises $46M more for AI drug discovery engine

7 years ago

Fresh from a $72M raise, Jeff Aronin's new lead rare disease drug is flagged as a failure

7 years ago

Hong Kong IPO delivers $421M to Innovent as another one of China's biotech unicorns hauls in big money

7 years ago

Alexion doles out $22M upfront for two preclinical RNAi drugs from Dicerna

7 years ago

Nav1.7 analgesic failures stack up as Biogen abandons vixotrigine after latest setback

7 years ago

Amid repeated stumbles, Pfizer and Eli Lilly tout their anti-NGF pain drug tanezumab — but questions linger

7 years ago

NeoGenomics spends $125M to expand ops; Cara hires Celgene exec as CMO

7 years ago

Antisense startup Stoke Therapeutics secures another $90M in series B funding

7 years ago

Bain’s Adam Koppel commits $350M to launching a new biotech that is carving out Pfizer’s neuro pipeline

7 years ago

First page Previous page 986 987 988989990 991 992 Next page Last page